1. Home
  2. RXO vs EWTX Comparison

RXO vs EWTX Comparison

Compare RXO & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RXO Inc.

RXO

RXO Inc.

N/A

Current Price

$28.45

Market Cap

4.0B

Sector

N/A

ML Signal

N/A

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

N/A

Current Price

$40.02

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RXO
EWTX
Founded
2022
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
4.3B
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
RXO
EWTX
Price
$28.45
$40.02
Analyst Decision
Hold
Strong Buy
Analyst Count
18
13
Target Price
$29.83
★ $56.17
AVG Volume (30 Days)
★ 3.4M
1.4M
Earning Date
10-29-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 72.81
N/A
EPS
N/A
★ 8.86
Revenue
★ $5,742,000,000.00
N/A
Revenue This Year
$21.30
N/A
Revenue Next Year
$10.66
N/A
P/E Ratio
★ N/A
$4.65
Revenue Growth
★ 26.20
N/A
52 Week Low
$11.18
$19.76
52 Week High
$29.90
$48.78

Technical Indicators

Market Signals
Indicator
RXO
EWTX
Relative Strength Index (RSI) 58.68 44.25
Support Level $28.14 $37.22
Resistance Level $28.68 $41.60
Average True Range (ATR) 0.43 3.20
MACD -0.13 -0.37
Stochastic Oscillator 63.48 26.45

Price Performance

Historical Comparison
RXO
EWTX

About RXO RXO Inc.

RXO Inc is a brokered transportation platform defined by technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Share on Social Networks: